Anti-Nucleocapsid (N) Rabbit mAb #VYN4

Aliases of the Protein (Antigen)

Severe acute respiratory syndrome coronavirus 2 nucleocapsid; 2019 novel coronavirus nucleoprotein, SARS-CoV-2 NP, SARS-CoV-2 N protein

Antigen Background

UniProt Entry: P0DTC9

Application Information

Antigen Molecular Weight: 46 kDa

Clonality: Rabbit monoclonal antibody

Clone ID: V400-G1

Species Reactivity: SARS-CoV-2

Applications Tested: Western blotting (WB), ELISA

Antigen Subcellular Location

Virion; Host ER-Golgi intermediate compartment; host Golgi apparatus; host perinuclear region

Immunogen

Recombinant SARS-CoV-2 nucleocapsid protein

Isotype

Rabbit IgG

Shipping

Supplied in PBS (pH 7.5) containing 0.01% sodium azide

Storage

Store at – 20°C

Recommended Dilutions

Western blotting (WB): 1:2,000

ELISA: 1:10,000

The single-stranded, plus-sense severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) genome encodes nonstructural replicase polyproteins as well as structural proteins such as spike (S), nucleocapsid (N), membrane (M) and envelop (E) proteins (Zhou et al., 2020). The N protein is abundantly expressed and highly immunogenic during SARS-CoV-2 infection (Cong et al., 2020). The middle or C-terminal region of the N protein has been shown to elicit antibody production during the immune response (Dutta et al., 2020). Although the surface electrostatic potential characteristics of SARS-CoV-2 N are different from other coronavirus N proteins (Kang et al., 2020), the sequences are conserved among these proteins (Dutta et al., 2020). Besides S protein, N protein is also considered a leading target antigen for vaccine development (Chen et al., 2020; Dutta et al., 2020).

 

Chen, W.H., Strych, U., Hotez, P.J., and Bottazzi, M.E. (2020). The SARS-CoV-2 Vaccine Pipeline: An Overview. Curr Trop Med Rep, 1-4.

Cong, Y., Ulasli, M., Schepers, H., Mauthe, M., V'Kovski, P., Kriegenburg, F., Thiel, V., de Haan, C.A.M., and Reggiori, F. (2020). Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. J Virol 94.

Dutta, N.K., Mazumdar, K., and Gordy, J.T. (2020). The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development. J Virol 94.

Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., et al. (2020). Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B 10, 1228-1238.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

• Recombinant antibodies with minimum batch-to-batch variations
• Thoroughly tested using SARS-CoV-2, human nasopharyngeal swabs, and rN
• No cross-reactivity with SARS or MERS

Anti-Nucleocapsid (N) Rabbit mAb #VYN4